4D Molecular Therapeutics FDMT Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from 4D Molecular Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: 4D Molecular Therapeutics’s 10-Q, filed November 10, 2025, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's return on equity?
- 4D Molecular Therapeutics (FDMT) reported return on equity of -45.4% in Q3 2025.
- How has 4D Molecular Therapeutics's return on equity changed year-over-year?
- 4D Molecular Therapeutics's return on equity decreased by 39.6% year-over-year, from -32.5% to -45.4%.
- What is the long-term trend for 4D Molecular Therapeutics's return on equity?
- Over 3 years (2021 to 2024), 4D Molecular Therapeutics's return on equity has grown at a 16.6% compound annual growth rate (CAGR), from -24.8% to -39.3%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.